MAPT and Alzheimer disease: The percentage of participants displaying a larger SUVR increase at week 49 was about 36% in both placebo and semorinemab arms; 35% and 37% in prodromal and mild AD, respectively; and 28%, 37%, and 43% in the low-, mid-, and high-tau groups, respectively.